Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1

Status

Recruiting 2Completed 2

Sponsor Class

INDUSTRY 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 4Lymphoid 4Plasma cell 2

Conditions

Leukemia, Myeloid, Acute 885Precursor Cell Lymphoblastic Leukemia-Lymphoma 511Hematologic Neoplasms 466Leukemia, Lymphocytic, Chronic, B-Cell 392Leukemia 337Myelodysplastic Syndromes 330Lymphoma 208Lymphoma, Non-Hodgkin 191Multiple Myeloma 146Leukemia, Myelogenous, Chronic, BCR-ABL Positive 142Recurrence 138Neoplasms 135Leukemia, Myelomonocytic, Chronic 112Burkitt Lymphoma 93Lymphoma, Mantle-Cell 92Lymphoma, Follicular 92Lymphoma, Large B-Cell, Diffuse 91Myeloproliferative Disorders 84Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 83Leukemia, Biphenotypic, Acute 81Lymphoma, B-Cell, Marginal Zone 75Hodgkin Disease 72Lymphoma, B-Cell 64Waldenstrom Macroglobulinemia 54Primary Myelofibrosis 54Leukemia, B-Cell 52Anemia, Refractory, with Excess of Blasts 46Leukemia, Myeloid, Chronic-Phase 41Hematologic Diseases 37Lymphoma, T-Cell 33

Interventions

venetoclax 1pirtobrutinib 1pembrolizumab 1ibrutinib 1fludarabine phosphate 1fludarabine 1acalabrutinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Chromosome 17 deletion × Other hematologic neoplasm × 1 year × Clear all
NCT07342478 2026-05-14

ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL

Newave Pharmaceutical Inc

Phase 3 Recruiting
306 enrolled
LymphoidOther hematologic neoplasm

Chromosome 17 deletion, Recurrence, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03204188 2026-01-30

Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
15 enrolled 9 charts
LymphoidOther hematologic neoplasm

Chromosome 17 deletion, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02337829 2026-01-08

Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL

Acerta Pharma BV

Phase 2 Completed
48 enrolled 12 charts
LymphoidOther hematologic neoplasm

Chromosome 17 deletion, Leukemia, Lymphoma, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02966756 2025-12-24

A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

AbbVie

Phase 2 Recruiting
110 enrolled
LymphoidOther hematologic neoplasm

Chromosome 17 deletion, Leukemia, Lymphoproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡